Innovative platforms and engineering approaches have created the next generation of bispecific antibodies with novel functionalities and features. However, the challenge is to identify attributes early in the process to make necessary improvements to constructs and avoid failures in the clinic late in the development process. Join this year’s leading experts as we explore one of the most exciting areas in biologics and discover what the newest platforms and engineering approaches are that promise an increasingly diverse array of new constructs and strategies that can achieve unprecedented efficacy.
Scientific Advisory Board:
Christian Klein, PhD, Distinguished Scientist & Head, Roche Innovation Center
Harald Kolmar, PhD, Professor and Head, Institute for Organic Chemistry and Biochemistry,
Technische Universität Darmstadt
Stefan Zielonka, PhD, Director and Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA